Company Overview of ChrysCapital
ChrysCapital is a private equity and venture capital firm specializing in management buy-outs or buy-ins, co-investments, public equity, PIPEs, growth capital in private and listed companies, and special situations including carve outs, joint ventures. The firm focuses on the business services; information technology; consumer goods and services; financial services; real estate; healthcare with a focus on pharmaceuticals, medical diagnostics and devices; infrastructure, power, and manufacturing sectors. It makes investments in companies based in or focusing on India and United States. The firm invests between $10 million and $300 million in companies with revenues ranging between $50 million...
St. James Court
Founded in 1999
Key Executives for ChrysCapital
Managing Director and Chief Financial Officer
Managing Director, Lead Partner, and Back-up Partner
Managing Director and Managing Partner
Compensation as of Fiscal Year 2014.
ChrysCapital Key Developments
Two Funds Are Reportedly In Talks To Buy Mankind Stake
May 14 15
ChrysCapital may sell its eight-year-old investment in Mankind Pharma Limited at a price that is nearly 10 times the value of its original investment. Capital International, Inc. (Capital International Private Equity Funds) and Warburg Pincus LLC are in the final stages of negotiation with ChrysCapital to buy its 11% stake in Mankind Pharma, according to two people familiar with the development. The deal size is estimated at around $225 million-$250 million, they said. “ChrysCapital has received serious pre-emptive offers from a couple of global PE funds that have been forwarded to the Juneja family, promoters of Mankind Pharma. As Fund-IV comes to an end, it is true that ChrysCapital is in talks with the Junejas to provide an exit for their investment in Mankind latest by the end of calendar year 2015,” said Sanjiv Kaul, managing director, ChrysCapital. ChrysCapital has appointed Ernst & Young (EY) and Avendus Capital Private Limited as bankers for the transaction, according to the first person cited above. The process will be completed by August 2015-September 2015, he said. Spokespeople for Warburg Pincus and Capital International declined to comment citing company policy, reported Mint, and Mankind declined to comment on the stake sale in an email, saying the company’s “spokesperson is travelling”.
Capital International Reportedly Eyeing Mankind Pharma
Feb 15 15
Capital International, Inc. may be interested in acquiring Mankind Pharma Limited. According to the news report, Capital International is said to be in talks to acquire 11% cent stake in Mankind Pharma for INR 13 billion to INR 15 billion. A possible deal could lead to ChrysCapital exiting its. According to people close to the matter, besides Capital International, at least two other leading PE investors are said to be interested in buying the stake in Mankind Pharma. The promoters are said to have no plans to sell more stake to the new PE investor. The news report mentioned that ChrysCapital Managing Director Sanjiv Kaul said, “The unsolicited and pre-emptive offers that were received by ChrysCapital have been forwarded to the promoters of Mankind.” It further added that Chuck Freadhoff, a spokesperson for the Capital Group said, “We cannot comment on any business discussions Capital International PE might or might not be having with any firm.”
ChrysCapital Reportedly Part-Exited Cyient
Jan 20 15
ChrysCapital is reported to have sold a portion of its investment in Cyient Limited (BSE:532175).
Similar Private Companies By Industry
Recent Private Companies Transactions